https://gjpb.de/index.php/gjpb/issue/feed German Journal of Pharmaceuticals and Biomaterials 2022-10-11T09:48:37-04:00 Open Journal Systems <p style="text-align: justify;"><strong>German Journal of Pharmaceuticals and Biomaterials (GJPB) [ p-ISSN: 2750-624X | e-ISSN:2750-6258 ] </strong>is an interdisciplinary peer reviewed open access scientific journal, publishes high-quality experimental and theoretical research that contributes significantly on all aspects of pharmaceutical sciences and biomaterials and their related subjects including their applications in human (covering experimental and clinical therapeutics). The mission is to publish scientific work that has followed laborious methodologies and to contribute to progress and development in both pharmaceuticals and biomaterials. <br />Scientific areas within the scope of this journal include but are not limited to pharmaceutics (all aspects of formulations and drug delivery systems, including oral, pulmonary, nasal, parenteral and transdermal delivery) and biopharmaceutics, including pharmaceutical biotechnology products, biochemistry and microbiology, pharmacology and toxicology, applied separation science (covers all areas of analytical/chromatography techniques), natural product drug discovery, medicinal chemistry, and bioactive polymers. This journal is also interested in work that addresses biomaterials but is not limited to covering all aspects of biomaterials with broad range of physical, biological and chemical sciences that support the design of biomaterials and the clinical/scientific disciplines in which they are used.</p> <p style="text-align: justify;"><strong>Country of Publication:</strong> Germany<br /><strong>Frequency:</strong> Quarterly (4 issues/year)</p> https://gjpb.de/index.php/gjpb/article/view/35 ADMET Prediction of synthesized Heterocyclic derivatives to treat renal cancer 2022-05-24T01:26:03-04:00 Rachel Cordeiro zeni.rachel4@gmail.com Saba Khan khansabawahid@gmail.com Heena Tajir heenatajir@gmail.com Afsha Bagwan Afshabagwan100@gmail.com Mohd Anas Shaikh Mohd.anas.shailk@hkcp.edu.in Ashish Gupta ashishgupta0498@gmail.com <p>A library of 121 potent, synthesized, and characterized compounds from different heterocyclic derivatives such as pyrimidine, phthalazine, benzothiazole, benzpyrazoline, indoline, benzimidazole, phthalazine, indole, quinoline, quinazoline were selected based on their anti-renal cancer activity. The Drug likeness, Bioactivity, Absorption, Distribution, Metabolism, Excretion, and Toxicity of all the screened compounds were predicted through Molinspiration, PreADMET, and Osiris software. After screening 121 compounds, 19 compounds showed drug-like properties and an absorption percentage better than the standard drug Sorafenib. These compounds were further assessed based on their distribution parameter and the compounds that showed plasma protein binding equal to or below 90% and blood-brain barrier penetration below 1.000 were selected, i.e., compounds 3, 23, 64, 65 were then further assessed for the toxicity. Osiris property explorer was used to predict drug relevance and toxicity of the synthesized compounds. Compounds 3 and 23 were non-toxic similar to the standard drug Sorafenib. Compounds 3 and 23 were found to be active as Kinase Inhibitors, with a bioactivity score of 0.2 and 0.6 compared to standard drug sorafenib, which scored 0.44. Therefore Compound 3 N-(4-fluoro-2-methoxyphenyl)-7-methyl-5,6,7,8-tetrahydropyrido [4',3':4,5] thieno[2,3-d] pyrimidin-4-amine and compound 23 1-(4-fluorophenyl)-3-methyl-N-phenyl-3a,7a-dihydro-1H-pyrazolo[3,4-d] pyrimidin-4-amine belonging to pyrimidine derivatives were considered as best and suggested to be taken further for preclinical and clinical trials. The pyrimidine derivatives with anti-renal cancer activity can serve as a scaffold for the design of renal cancer targeting agents and motivates the further development of effective and safer compounds.</p> 2022-10-11T00:00:00-04:00 Copyright (c) 2022 Rachel Cordeiro, Saba Khan, Heena Tajir, Afsha Bagwan, Mohd Anas Shaikh , Ashish Gupta https://gjpb.de/index.php/gjpb/article/view/44 Effects of carboxymethylated gum obtained from Entandophragma angolense tree on the compressional and release properties of ibuprofen tablets 2022-07-09T10:30:04-04:00 Oladapo A detunji adetunjioladapo@gmail.com Olubunmi M Ajakore olubunmiajakore@gmail.com Oludele A Itiola oprofit@gmail.com <p>The incorporation of modified polymers in drug formulations is primarily due to their low toxicity, affordability, availability, compatibility with biological membranes, economic feasibility and bio-degradability.This study investigated the compressional and release characteristics of ibuprofen tablet formulations containing natural and modified <em>Entandophragma angolense</em> gum. <em>Entandophragma angolense </em>gum (ENTA) was extracted and modified by carboxymethylation to yield CENTA. Ibuprofen tablets containing varying binder concentrations (2.5-10% w/w) of ENTA and CENTA (compared with gelatin BP) were formulated by wet granulation. Crushing strength (CS) and friability (FR) were used in assessing the mechanical properties of the tablets, while disintegration and dissolution times accounted for drug release parameters. Density measurements, Kawakita equations and Heckel plots were used to assess the compressional properties of the formulations. The results were analysed using ANOVA at ɑ0.05. Generally, there was a direct relationship between the concentration of the polymers and the CS of the tablets, while an inverse relationship was observed for FR. The CS ranked ENTA &gt; CENTA &gt; gelatin BP. Carboxymethylation of ENTA enhanced drug release (t<sub>30%</sub> and t<sub>80%</sub>). Formulations containing CENTA had a slower and faster onset of plastic deformation; mean yield pressure (P<sub>y</sub>), ranked ENTA &gt; CENTA &gt; gelatin BP. A measure of the rearrangement phase at the early stages of compression (D<sub>B</sub>) was highest for CENTA at all concentrations. CENTA compared favourably with gelatin BP and showed better mechanical and release characteristics than ENTA. Also, CENTA shows good potential as a binder in fast disintegrating ibuprofen tablets, especially when incorporated at low concentrations.</p> 2022-10-11T00:00:00-04:00 Copyright (c) 2022 Oladapo A detunji, Olubunmi M Ajakore, Oludele A Itiola https://gjpb.de/index.php/gjpb/article/view/70 Editor 2022-10-10T10:10:17-04:00 Editor editor@gjpb.de <p><strong>Front Matter</strong></p> 2022-10-11T00:00:00-04:00 Copyright (c) 2022 Editor https://gjpb.de/index.php/gjpb/article/view/42 Saraca asoca: A scoping review on the phytoconstituents, bioactives and their therapeutic effects 2022-05-27T13:49:59-04:00 Sahil Salvi salvisahil604@gmail.com Ryan Varghese ryanvarghese14@gmail.com Gargi Digholkar gdigholkar@gmail.com Abha Deshpande aabhadeshpande3@gmail.com Chinmay Malvankar chinmaymalvankar60@gmail.com Atmaram Pawar dratmarampawar@gmail.com Dileep Kumar dileep.0@gmail.com <p><em>Saraca asoca </em>or<em> S. asoca</em>, belonging to the family Caesalpinaceae, is popularly known as Ashoka and is a valuable indigenous plant of traditional and pharmacological significance. With a growing number of people seeking treatments and health practices devoid of synthetic medicines' adverse effects, medicinal herbs are becoming more mainstream. Ashoka has traditionally been employed to treat dysentery, colic, piles, biliousness, dyspepsia, and ulcers and is also known to display CNS depressant activity and regulate irregular menstrual cycles. The qualitative phytoconstituents of Ashoka's leaves, flowers, fruits, and bark, such as glycosides, flavonoids, tannins, and saponins, carry vast potential in therapeutic and diagnostic techniques. Formulations containing these components can efficiently exert anti-microbial, anti-inflammatory, anti-menorrhagia, anti-diabetic, anthelmintic, and analgesic activity. This review focuses on research associated with the medicinal qualities, phytochemistry, and pharmacological profile of Saraca asoca (Roxb.), De. wild.</p> 2022-10-11T00:00:00-04:00 Copyright (c) 2022 Sahil Salvi, Ryan Varghese, Gargi Digholkar, Abha Deshpande, Chinmay Malvankar, Atmaram Pawar, Dileep Kumar https://gjpb.de/index.php/gjpb/article/view/72 Conflicts of interest in scholarly communication: what is it and how to avoid it? 2022-10-11T09:14:59-04:00 Paras Sharma paraszee05@gmail.com <p style="text-align: justify;">The journals often require disclosure of the conflicts of interest from all the stakeholders involved in the peer review and editorial process. The international committee of medical journal editors (ICMJE) defines conflicts of interest as "The potential for conflict of interest and bias exists when professional judgment concerning a primary interest (such as patients' welfare or the validity of research) may be influenced by a secondary interest (such as financial gain)" [1]. Another definition states, "A conflict of interest is a set of circumstances that creates a risk that professional judgment or actions regarding a primary interest will be unduly influenced by a secondary interest" [2]. It is a situation where the same individual is involved with two competing interests, one of which may involve unethical motivation or benefit or financial interest. Therefore, the COI involves a real, apparent, or potential violation of the trust that others have in the process being conducted or in the researchers participating in the research. Although conflicts of interest (COI) are not new in biomedical research, it was rarely reported until the late 90s, when serious reports of linkage between private companies and academic institutions [3]. It gained more attention with the increasing number of sponsored research on commercial applications leading to doubt about how sponsorship or partial financial support affects the research outcome. The COI is a significant concern for biomedical and pharmaceutical journals. The organizations such as the International Committee of Medical Journal Editors, the World Association of Medical Editors and the Committee on Publication Ethics (COPE) have launched initiatives to establish international standards for Conflict of Interest (COI) disclosure. COPE requires its member journals to comply with its Code of Conduct for Journal Editors. Although these initiatives helped a lot to improve the situation, there is still a lack of awareness and understanding of COI, especially among budding researchers.</p> 2022-10-11T00:00:00-04:00 Copyright (c) 2022 Paras Sharma